Clinical trials: open to volunteers, in Norway
Endometrial Cancer
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
DESTINY-Endometrial01 will investigate the efficacy of first-line T-DXd + rilvegostomig (Arm A) and/or T-DXd+ pembrolizumab (Arm B) when compared to chemotherapy (carboplatin + paclitaxel) + pembrolizumab (Arm C), by assessment…
- Trial name
- DE-01 (NCT06989112)
- Testing
- Trastuzumab deruxtecan, Rilvegostomig, Pembrolizumab
- Where
- 257 sites in United States, Australia and 21 more
- Volunteers
- 600 people
- Sponsor
- AstraZeneca
Difficulties of Emotion Regulation, Self-harm Behavior
DBT Skill Training for Autistic Adults With Difficulties in Emotion Regulation.
One in 44 has autism, 70% of them have additional mental health challenges. Currently, this patient population does not have access to effective treatment within specialist healthcare services and has struggled to benefit from…
- Conditions
- Difficulties of Emotion Regulation, Self-harm Behavior, Autism Spectrum Disorder
- Trial name
- NCT07021274
- Testing
- DBT skills training adjusted to autistic needs
- Where
- Norway
- Volunteers
- 15 people
- Sponsor
- Helse Møre og Romsdal HF
Ovarian Neoplasms, Ovarian Cancer
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
Researchers are looking for new ways to treat ovarian cancer (OC). Current treatment for OC may start with surgery to remove as much of the cancer as possible. After surgery, people may receive chemotherapy.
- Trial name
- TroFuse-021 (NCT07318558)
- Testing
- Sacituzumab tirumotecan, Bevacizumab, Rescue Medications
- Where
- 167 sites in United States, Argentina and 28 more
- Volunteers
- 900 people
- Sponsor
- Merck Sharp & Dohme LLC
Proteinuric Kidney Diseases
PODOMOUNT-Basket, a Study to Test Whether BI 764198 Helps Adults and Adolescents With Different Types of Kidney Disease
This study is open to adults with certain kidney conditions, including secondary focal segmental glomerulosclerosis (sFSGS), treatment-resistant primary minimal change disease (TR-pMCD), Alport Syndrome (AS), and…
- Trial name
- NCT07355296
- Testing
- BI 764198
- Where
- 159 sites in United States, Argentina and 31 more
- Volunteers
- 132 people
- Sponsor
- Boehringer Ingelheim
Acute Ischemic Stroke
A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Person Was Last Seen Well
This study is open to adults who had an acute stroke caused by a clot blocking a blood vessel in the brain (acute ischemic stroke).
- Trial name
- TENACITY (NCT07361302)
- Testing
- Tenecteplase, Standard of care treatment
- Where
- 254 sites in Argentina, Australia and 14 more
- Volunteers
- 1,325 people
- Sponsor
- Boehringer Ingelheim
Extrapulmonary Neuroendocrine Cancer (epNEC)
DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy
This study is open to adults with advanced extrapulmonary neuroendocrine cancer. The purpose of this study is to find out if a study medicine called obrixtamig plus standard chemotherapy (carboplatin and etoposide) improves…
- Trial name
- NCT07544654
- Testing
- Obrixtamig, Carboplatin, Etoposide
- Where
- 166 sites in United States, Argentina and 27 more
- Volunteers
- 390 people
- Sponsor
- Boehringer Ingelheim
Colitis, Ulcerative
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis
The purpose of this study is to assess how well JNJ-78934804 works (efficacy) and how safe it is (safety) as compared to guselkumab at Week 48 in participants with moderately to severely active ulcerative colitis (UC, a chronic…
- Trial name
- DUET ENCORE-UC (NCT07577856)
- Testing
- JNJ-78934804, Guselkumab
- Where
- 279 sites in United States, Argentina and 30 more
- Volunteers
- 644 people
- Sponsor
- Janssen Research & Development, LLC
Head & Neck Cancer, Oral Mucositis
A Clinical Study to Compare BupiZenge With Lidocaine for Pain Due to Oral Mucositis in Patients With Head and Neck Cancer.
Most patients who receive radiation therapy for head and neck cancer develop painful sores in the mouth called oral mucositis. For many of them, these sores are severe and result in debilitating pain.
- Trial name
- BEAM-Pain (NCT07672236)
- Testing
- BupiZenge 25 mg, Lidocaine viscous 2%
- Where
- 11 sites in Denmark, Germany and 2 more
- Volunteers
- 150 people
- Sponsor
- OncoZenge AB
Acute Ischemic Stroke
Infarct Growth After Intravenous Tocilizumab in Adults With Acute Ischemic Stroke Undergoing Endovascular Thrombectomy - ILLUMINATE
The goal of this phase II, placebo-controlled intervention study is to investigate whether tocilizumab, an interleukin-6 (IL-6) receptor inhibitor, may have a neuroprotective effect by reducing infarct growth in adults with acute…
- Trial name
- Illuminate (NCT07870681)
- Testing
- Tociliuzumab
- Where
- 6 sites in Denmark, Norway
- Volunteers
- 156 people
- Sponsor
- Oslo University Hospital
Non-valvular Atrial Fibrillation (AF)
Vortosiran in Atrial Fibrillation
This is a randomised, actively controlled Phase IIb trial to evaluate the safety and pharmacodynamics (PD) of two blinded doses of subcutaneously administered vortosiran and open-label apixaban in patients with AF.
- Trial name
- NCT07870889
- Testing
- Vortosiran, Apixaban
- Where
- 15 sites in Denmark, Norway and 2 more
- Volunteers
- 150 people
- Sponsor
- Ribocure Pharmaceuticals AB
Immune Thrombocytopenia (ITP)
A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia
The purpose of the phase 1 part of this study was to evaluate how well pirtobrutinib is tolerated and what side effects may occur.
- Trial name
- NCT06721013
- Testing
- Pirtobrutinib
- Where
- 43 sites in United States, China and 8 more
- Volunteers
- 68 people
- Sponsor
- Eli Lilly and Company
Non-Small Cell Lung Cancer
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
A Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after failure of EGFR TKI Therapy
- Trial name
- NCT07100080
- Testing
- Iza-bren, Carboplatin, Cisplatin
- Where
- 187 sites in United States, Argentina and 23 more
- Volunteers
- 500 people
- Sponsor
- Bristol-Myers Squibb
CRC (Colorectal Cancer)
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
The purpose of this study is to evaluate the efficacy and safety of standard-of-care chemotherapy and bevacizumab with or without INCA33890 in the first-line treatment of metastatic microsatellite stable colorectal cancer.
- Trial name
- NCT07284849
- Testing
- INCA33890, Bevacizumab, FOLFOX
- Where
- 293 sites in United States, Argentina and 20 more
- Volunteers
- 700 people
- Sponsor
- Incyte Corporation
Glaucoma
Trabeculectomy Versus MicroShunt Implantation in Glaucoma Surgery (TIGER)
Glaucoma is an eye disease causing vision loss if not treated adequately. The prevalence is around 1.5%, exponentially increasing to more than 10% in the elderly.
- Trial name
- NCT07869108
- Testing
- Preserflo MicroShunt, Trabeculectomy
- Where
- Norway
- Volunteers
- 100 people
- Sponsor
- Oslo University Hospital
Complex Regional Pain Syndrome (CRPS)
Clinical and Cerebral Changes Following Multifaceted Rehabilitation of Complex Regional Pain Syndrome
This study investigates the clinical effects of an individually tailored rehabilitation program for patients with Complex Regional Pain Syndrome (CRPS).
- Trial name
- NCT02753335
- Testing
- Individualized CRPS Rehabilitation
- Where
- Norway
- Volunteers
- 12 people
- Sponsor
- University Hospital of North Norway
Melanoma Stage Iv
Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study)
This is a phase II, open label, randomised trial of ipilimumab and nivolumab with concurrent intracranial stereotactic radiotherapy versus ipilimumab and nivolumab alone in patients with asymptomatic, untreated melanoma brain…
- Trial name
- ABC-X (NCT03340129)
- Testing
- Ipilimumab, Nivolumab, Stereotactic Radiotherapy
- Where
- 9 sites in Australia, Norway
- Volunteers
- 218 people
- Sponsor
- Melanoma Institute Australia
Pulmonary Sarcoidosis
Efficacy and Safety Study of OATD-01 in Patients With Active Pulmonary Sarcoidosis
This is a Phase 2, randomized, double-blind, placebo-controlled, adaptive, multicenter study to evaluate the efficacy, safety, tolerability, Pharmacodynamics (PD), and Pharmacokinetics (PK) of OATD-01 in the treatment of subjects…
- Trial name
- NCT06205121
- Testing
- OATD-01
- Where
- 28 sites in United States, Denmark and 6 more
- Volunteers
- 96 people
- Sponsor
- Molecure S.A.
Metabolic Dysfunction-Associated Steatotic Liver Disease
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
The main purpose of the SYNERGY-OUTCOMES study is to find out whether retatrutide and tirzepatide can prevent major adverse liver outcomes (MALO) in people with high-risk metabolic dysfunction-associated steatotic liver disease…
- Trial name
- NCT07165028
- Testing
- Tirzepatide, Retatrutide
- Where
- 563 sites in United States, Argentina and 32 more
- Volunteers
- 4,500 people
- Sponsor
- Eli Lilly and Company
Ovarian Neoplasms, Fallopian Tube Neoplasms
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
This is a clinical study that has three parts. It is testing a potential new medicine called Sofetabart Mipitecan (Sofe-M) for people with certain types of ovarian, peritoneal, and fallopian tube cancers.
- Conditions
- Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms, Neoplasm Metastasis
- Trial name
- FRAmework-01 (NCT07213804)
- Testing
- Sofetabart Mipitecan, Paclitaxel, Topotecan
- Where
- 265 sites in United States, Australia and 25 more
- Volunteers
- 1,630 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 1
A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults
The purpose of this study is to find out if baricitinib can delay the onset of clinical type 1 diabetes (T1D) in people who are at high risk to develop T1D. Participation in the study will last up to approximately 5 years.
- Trial name
- BARICADE-DELAY (NCT07222137)
- Testing
- Baricitinib
- Where
- 112 sites in United States, Australia and 17 more
- Volunteers
- 150 people
- Sponsor
- Eli Lilly and Company